Found 5 matching trials
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
PHASE1The purpose of this study is to determine the safety and efficacy of a PEPI...
Location
Duke University Medical Center
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
EARLY_PHASE1Gliomas are a heterogeneous group of tumors arising from glial cells in the...
Location
Biogenea Pharmaceuticals Ltd
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
PHASE1The trial will address safety and tolerability of the combination of the ID...
Location
Charité Berlin, Neurosurgery
Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas
PHASE1The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrog...
Location
Charité Berlin, Neurosurgery
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
PHASE1Potential subjects with progressive Grade II primary brain tumor that have ...
Location
Duke University Medical Center